Exacerbation of pityriasis rubra pilaris under efalizumab therapy

Dermatology

Volumn 215, Issue 1, 2007, Pages 72-75

  Klein, A ^a   Szeimies, R M ^a   Landthaler, M ^a   Karrer, S ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Biologics; Infliximab; Pityriasis rubra pilaris; Psoriasis vulgaris; TNF alpha inhibitors

Indexed keywords

ADALIMUMAB; CALCIPOTRIOL; CORTICOSTEROID; EFALIZUMAB; ETANERCEPT; ETRETIN; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 2; INTERCELLULAR ADHESION MOLECULE 3; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD11A; PREDNICARBATE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CASE REPORT; CHILL; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG WITHDRAWAL; EPIDIDYMITIS; ERYTHRODERMA; FEMALE; FEVER; HEADACHE; HUMAN; KERATOSIS PALMOPLANTARIS; MYALGIA; NAUSEA; PAIN; PANCREATITIS; PITYRIASIS RUBRA PILARIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUVA; PYELONEPHRITIS; SIALOADENITIS; SKIN BIOPSY;

ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PITYRIASIS RUBRA PILARIS; PUVA THERAPY; RETREATMENT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34250881469     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102039     Document Type: Article

References (23)

1. Schleyer V, Landthaler M, Szeimies RM: Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venereol 2005;19:1-20.
2. Dubertret L, Sterry W, Bos JD, et al: Clinical experience acquired with the efalizumab (Raptiva®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170-181.
3. Pariser DM, Gordon KB, Papp KA, et al: Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled phase III trials - part I. J Cutan Med Surg 2005;6:303-312.
4. Papp KA, Bressinck R, Fretzin S, Goffe B, et al: Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006;45:605-614.
5. De Groot M, de Rie MA, Bos JD: Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris. Br J Dermatol 2005;153:843-844.
6. Thielen AM, Kuenzli S, Saurat JH: Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology 2005;211:209-217.
7. Bentley DD, Graves JE, Smith DI, Heffernan MP: Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2006;54:242-243.
8. Bang B, Gniadecki R: Severe exacerbation of psoriatic arthritis during treatment with efalizumab: a case report. Acta Derm Venereol 2006;86:456-457.
9. Huber A, Gaffal E, Bieber T, et al: Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol 2006;86:254-255.
10. Weinberg JM, Siegfried EC: Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol 2006;142:555-558.
11. Kaelin U, Hassan AS, Braathen LR, Yawalkar N: Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol 2006;55:529-532.
12. Cheng A, Mann C: Oral erosive lichen planus treated with efalizumab. Arch Dermatol 2006;142:680-682.
13. Artik S, Kuhn A, Neumann NJ, Ruzicka T, Megahed M: Pityriasis rubra pilaris. Hautarzt 2004;55:980-983.
14. Evangelou G, Murdoch SR, Palamares I, Rhodes LE: Photoaggravated pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed 2005;21:272-274.
15. Herbst RA, Vogelbruch M, Ehnis A, Kiehl P, Kapp A, Weiss J: Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol 2000;142:574.
16. Coras B, Vogt T, Ulrich H, Landthaler M, Hohenleutner U: Fumaric acid esters therapy: a new treatment modality in pityriasis rubra pilaris? Br J Dermatol 2005;152:388-389.
17. Selvaag E, Haedersdal M, Thomsen K: Pityriasis rubra pilaris: a retrospective study of 12 patients. J Eur Acad Dermatol Venereol 2000;14:514-515.
18. Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA: Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003;7:382-386.
19. Manoharan S, White S, Gumparthy K: Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol 2006;47:124-129.
20. Liao WC, Mutasim DF: Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol 2005;141:423-425.
21. Jullien D, Prinz JC, Langley RGB, et al: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004;208:297-306.
22. Margo CM, Crowson AN: The clinical and histomorphological features of pityriasis rubra pilaris. J Cutan Pathol 1997;24:416-424.
23. Braun-Falco O, Ryckmanns F, Schmoeckel C, Landthaler M: Pityriasis rubra pilaris: a clinico-pathological and therapeutic study with special reference to histochemistry, autoradiography, and electron microscopy. Arch Dermatol Res 1983;275:287-295.